Emergent Biosolutions Inc.

EBS Healthcare Drug Manufacturers Specialty & Generic

Emergent Biosolutions Inc.’s revenue for fiscal 2025 (year ended December 2025) was $742.9 million, down 28.8% from fiscal 2024. In the quarter to June 2026, revenue grew 66.3%, EPS fell 1,486.4%, free cash flow fell 47.7% and total debt fell 12.9%, each against the same quarter a year earlier.

6.38 0.80 −11.14%
Market cap
$368.1M
P/E
0.0×
Fwd P/E
−26.5×
Dividend yield
—
F-score
6/9
Altman Z
1.63
Beneish M
−3.56
Dividend safety
n/a

A Cash Flow Statement is a financial report that details the cash inflows and outflows of a company over a specific period. It is divided into three sections: operating activities, investing activities, and financing activities. This statement helps assess the company’s liquidity, solvency, and overall financial health. By tracking cash movements, it provides insights into the company's ability to generate cash to fund operations, pay debts, and invest in growth. Businesses and investors use it to evaluate the sustainability of a company's cash flow and its financial stability.

Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16
Net Income
52.60 (190.60) (760.50) (211.60) 219.50 305.10 54.50 62.70 82.60 51.80
Depreciation & Amortization
105.60 116.20 364.60 154.10 169.60 118.00 113.70 63.10 44.30 38.20
Non Cash Items (Other)
37.90 48.00 264.70 25.50 76.10 104.10 78.20 35.30 27.50 8.90
Accounts Receivable Change
25.50 (24.40) (21.60) 118.10 (16.20) 49.00 (8.20) (94.20) (4.80) (22.40)
Change in inventories
(30.30) (24.50) 0.60 (57.10) (66.60) (83.20) (16.70) (1.90) 6.10 (9.00)
Accounts Payable Change
(8.40) (33.00) 10.60 (14.00) (1.60) 18.70 16.50 (7.00) 16.10 (14.80)
Change in payables and accrued liability
(27.50) (5.90) (66.10) (67.50) (5.20) 41.20 (10.90) (3.20) 4.90 2.80
Income tax paid
(1.70) 23.30 (16.20) 28.70 (31.30) 1.10 (11.70) (5.10) 20.10 (3.40)
Change in other assets and liabilities
16.90 149.60 17.60 (10.30) (24.10) (18.00) (39.10) (13.00) 11.30 2.50
Operating Cash Flow
170.60 58.70 (206.30) (34.10) 320.20 536.00 188.00 41.80 208.10 54.60
Capital expenditures
24.40 (15.00) (51.60) (115.80) (224.10) (141.00) (86.90) (69.50) (54.80) (76.20)
Change in intangibles (net)
— 0.00 0.00 (21.80) 0.00 0.00 — — — —
Net Aquisitions
— 110.20 270.20 (243.70) — — — (827.70) (195.10) —
Other investing activities
45.00 30.00 (6.30) (27.70) (15.00) (10.00) (10.00) (8.90) (16.20) (35.77)
Investing cash flow
69.40 125.20 212.30 (381.30) (224.10) (151.00) (96.90) (897.20) (249.90) (76.20)
Repayment/Issuance of Debt (Net)
(112.50) (198.40) (543.40) 564.20 (35.90) 62.90 13.70 795.20 (20.00) —
Equity Repurchase (Common, Net)
(22.70) 22.70 — (82.10) (106.00) — 8.20 (0.10) (13.80) 17.10
Other financial activities
(1.40) (14.30) 7.70 (0.90) 0.90 6.60 (49.60) (6.40) (17.60) (36.90)
Financing cash flow
(136.60) (190.00) (535.70) 481.20 (141.00) 69.50 (35.90) 788.70 (51.40) (19.80)
Exchange Rate Adjustment
0.10 0.00 (1.20) 0.50 (0.30) (1.00) 0.40 (0.20) 0.00 0.10
Change in Cash
103.50 (6.10) (530.90) 66.30 (45.20) 453.50 55.60 (66.90) (93.20) (41.30)
Beginning Cash
105.60 111.70 642.60 576.30 621.50 168.00 112.40 179.30 272.50 312.80
Ending Cash
209.10 105.60 111.70 642.60 576.30 621.50 168.00 112.40 179.30 271.50
Stock Based Compensation
16.20 18.00 23.10 45.10 42.40 51.00 26.70 23.20 15.20 18.50
Dividends Paid (Common)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Cash/Marketcap
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Assets Liabilities Change (Total)
(25.50) 85.10 (75.10) (2.10) (145.00) 8.80 (58.40) (119.30) 53.70 (44.30)
Issuance/Purchase of Shares
(22.70) 22.70 — (82.10) (106.00) — 8.20 (0.10) (13.80) 17.10
Other line items
Revenue per Employee
0.83 1.16 0.66 0.45 0.73 0.71 0.60 0.46 0.45 0.45

Fold the line items

In millions of $ except per-share values · columns are period end dates